ライフサイエンスコーパス: bloat

1 tients (64% with abdominal pain and 70% with bloating).

2 , relating these changes to the sensation of bloating.

3 llenging symptoms of pain, constipation, and bloating.

4 mptoms of abdominal fullness, distension, or bloating.

5 oms such as nausea, vomiting, diarrhoea, and bloating.

6 resented with generalized abdominal pain and bloating.

7 ith diarrhoea, vomiting, abdominal pain, and bloating.

8 s (15%), including loose stools, nausea, and bloating.

9 ation, chronic functional abdominal pain, or bloating.

10 comfort for at least 2 days/wk) and reported bloating.

11 stency, straining, abdominal discomfort, and bloating.

12 mon side effects were diarrhea, cramping, or bloating (11/31, 35%).

13 terval (CI): -2.66 to -1.83; P < 0.001], gas bloating [11% vs 18%; relative risk (RR) 0.59; 95% CI: 0

14 ed abdominal size; 3.6 (95% CI, 1.8-7.0) for bloating; 2.5 (95% CI, 1.3-4.8) for urinary urgency; and

15 e other gastrointestinal manifestations were bloating (20%), aphthous stomatitis (18%), alternating b

16 common were back pain (45%), fatigue (34%), bloating (27%), constipation (24%), abdominal pain (22%)

17 imum pain, 2.1 +/- 0.4; nausea, 2.2 +/- 0.4; bloating, 3.7 +/- 0.2).

18 with mastocytosis than in healthy subjects: bloating (33% vs 7.2%, P < .0001), abdominal pain (27.3%

19 40-0.99; P = 0.05), and inability to relieve bloating (34% vs 44%; RR: 0.74; 95% CI: 0.55-0.99; P = 0

20 in the placebo group had adequate relief of bloating (39.5% vs. 28.7%, P=0.005, in TARGET 1; 41.0% v

21 stroparesis were more severe in PN than nPN: bloating (4.05 +/- 1.17 vs. 2.99 +/- 1.61, p < 0.01), ab

22 -like symptoms (42%), bloating (68%), severe bloating (44%), and nausea (23%) were significantly high

23 rved, and among their common complaints were bloating (61%) and heartburn (40%).

24 The frequencies of IBS-like symptoms (42%), bloating (68%), severe bloating (44%), and nausea (23%)

25 antly less reduced and the prevalence of gas bloating (7.1% vs. 21.4%; P = 0.242) and increased flatu

26 common symptoms reported by respondents were bloating (75%), abdominal pain (72%), chronic fatigue (6

27 he most common symptoms were diarrhea (86%), bloating (77.5%), and abdominal pain (71.3%).

28 ive measures of GI discomfort (e.g., nausea, bloating, abdominal discomfort) with mild to severe adve

29 ms associated with lymphangioleiomyomas were bloating, abdominal pain, and edema of the lower extremi

30 mine general abdominal discomfort, abdominal bloating, abdominal pain, and flatulence on a scale of 1

31 provided significant relief of IBS symptoms, bloating, abdominal pain, and loose or watery stools.

32 ersive symptom scores (fullness, distention, bloating, abdominal pain, and sickness) in CD participan

33 obal IBS symptoms and individual symptoms of bloating, abdominal pain, and stool consistency during t

34 s assessed by daily ratings of IBS symptoms, bloating, abdominal pain, and stool consistency.

35 h gastroesophageal reflux disease, diarrhea, bloating, abdominal pain, constipation, fatigue, osteope

36 the period of high lactose intake; however, bloating, abdominal pain, diarrhea, and the global perce

37 luding early satiety, postprandial fullness, bloating, abdominal swelling, nausea, vomiting, and retc

38 is usually divided into five stages: fresh, bloat, active decay, advanced decay, and skeletal remain

39 pain, excessive fullness, early satiety, and bloating; all r > 0.35, P < 0.05).

40 IBO was extended to explain symptoms such as bloating, altered bowel habit and discomfort among indiv

41 pathway genes are upregulated by intestinal bloating and are required for microbial aversion behavio

42 ymptom of abdominal pain in conjunction with bloating and bowel movement disorder.

43 More severe symptoms (bloating and constipation) were characteristic of patien

44 iagnosis of IBS; in particular, inclusion of bloating and de-emphasis of pain as criteria were consid

45 visits for abdominal pain, constipation, and bloating and diagnoses of IBS; and IMS Health's National

46 -aged females complaining of abdominal pain, bloating and diarrhea.

47 observations in IBS, including postprandial bloating and distension, altered motility, visceral hype

48 Bloating and distention may differ pathophysiologically

49 Although postoperative gas-bloating and dysphagia are frequent, long-term patients'

50 Gas-bloating and dysphagia occurred in 53% (95% CI, 20%-83%)

51 ms of abdominal pain, bowel dysfunction, and bloating and exclusion of alarm symptoms such as uninten

52 utcomes comprised, IBS symptom scores, pain, bloating and flatulence levels, stool frequency, stool c

53 s were found for severity of abdominal pain, bloating and flatulence, and QoL score between prebiotic

54 re air venting from the stomach and less gas bloating and flatulence, whereas reflux is reduced to a

55 e excess intestinal gas, causing undesirable bloating and flatulence.

56 With regard to physical symptoms, bloating and food cravings showed greater severity in wo

57 Overweight patients had more bloating and gastric retention at 2 hours but less sever

58 o benefited from a reduction in belching and bloating and in dizziness, headache and muscle cramps, a

59 e symptoms including inability to belch, gas bloating and increased flatulence.

60 may be targeted to ameliorate the abdominal bloating and loss of appetite typical of gastric motilit

61 in was most common, while IBS-like symptoms, bloating and nausea also occurred more often than in the

62 aily activities, recording their symptoms of bloating and pain together with bowel habit.

63 In contrast, scores of postprandial bloating and pain were higher with increased body mass i

64 year-old female who presented with abdominal bloating and recurrent falls precipitated by vertigo, de

65 ealthcare seeking were presence of abdominal bloating and vomiting (p < 0.05).

66 Abdominal pain, bloating and weight loss were the commonest symptoms ass

67 ssion of increased rectal gas, and abdominal bloating), and five were examined for breath hydrogen ex

68 ndrome with constipation, 15 with functional bloating, and 3 with irritable bowel syndrome with alter

69 he developed symptoms of diarrhea, abdominal bloating, and discomfort in the midepigastrium.

70 vomiting, as well as nausea, abdominal pain, bloating, and early satiety compared with placebo (compo

71 me (IBS) is characterized by abdominal pain, bloating, and erratic bowel habits.

72 t, transient symptoms (abdominal distension, bloating, and flatulence) without increased breath hydro

73 abdominal symptoms, including discomfort and bloating, and global measures of IBS-C compared with pla

74 experience fatigue, fever, chills, abdominal bloating, and loss of appetite.

75 continued fatigue, fever, chills, abdominal bloating, and loss of appetite.

76 along with scores for postprandial fullness, bloating, and nausea (all P < .05).

77 It classically presents as chronic diarrhea, bloating, and nausea in addition to malabsorption sympto

78 ht upper quadrant discomfort, early satiety, bloating, and nausea.

79 significantly the higher levels of pain, gas/bloating, and nausea/vomiting compared to the Normal gro

80 pairment of intestinal propulsion, abdominal bloating, and pain.

81 it only occurs in half of patients reporting bloating, and the 2 only correlate in IBS-constipation.

82 onspecific symptoms, such as abdominal pain, bloating, and urinary urgency and frequency, and about 8

83 %) experiencing nausea, diarrhoea, abdominal bloating, and weight loss greater than 2 kg (mean of 4 k

84 ptoms, abdominal discomfort, abdominal pain, bloating, and/or flatulence.

85 sex, for every 1,000 patients with abdominal bloating, assessment incorporating information from bloo

86 pt less heartburn at 3 and 6 months and less bloating at 12 months with nonabsorbable mesh; more hear

87 dpoints were improvement of IBS symptoms and bloating at 12 weeks (response).

88 ting in vague gastrointestinal symptoms with bloating being most commonly reported.

89 lish general practice with abdominal pain or bloating between January 2007 and October 2016.

90 generated a novel mouse mutant termed Blad (Bloated Bladder).

91 ic complaints, such as breast tenderness and bloating, can also be problematic.

92 We demonstrate that intestinal bloating caused by calcineurin inhibition mimics the eff

93 pparatus is composed of collapsed stacks and bloated cisternae in these cells.

94 Whereas the majority of FGID, including IBS, bloating, constipation, chronic functional abdominal pai

95 including globus, rumination syndrome, IBS, bloating, constipation, functional abdominal pain, sphin

96 Bloating correlated strongly only with distention in IBS

97 no-switch group, but rates of diarrhoea and bloating decreased compared with baseline from week 4 to

98 l proliferations are characterized either by bloated dendritic melanocytes with enlarged cell compone

99 visits for abdominal pain, constipation, and bloating; diagnoses of irritable bowel syndrome (IBS); a

100 ymptoms traditionally linked to SIBO include bloating, diarrhea, and abdominal pain/discomfort.

101 rted 7 multi-item scales: reflux, distention/bloating, diarrhea, fecal soilage, constipation, emotion

102 ion [grade 3]; recurrence of abdominal pain, bloating, diarrhoea, and urinary tract infection [grade

103 Breast tenderness and bloating did not result from sodium retention in the lut

104 sphagia for esophageal cancer; and abdominal bloating/distension (in women) for ovarian cancer.

105 of abdominal pain (either sex) and abdominal bloating/distension (men only) were for non-abdominal ca

106 : dysphagia (n = 86,193 patients), abdominal bloating/distension (n = 100,856), change in bowel habit

107 :50% (rectal bleeding) to 73%:27% (abdominal bloating/distension).

108 ctional diarrhea (FDr); functional abdominal bloating/distention (FAB/D); and unspecified FBD (U-FBD)

109 end points included nausea, abdominal pain, bloating, early satiety, as well as the composite score

110 tion of Rtns/Yop1 does not, however, prevent bloated ER tubules from being pulled from the mother cis

111 estive symptoms (abdominal pain, borborygmi, bloating, excess flatus, and stools/day) between cinnamo

112 th treatment-refractory IBS with predominant bloating, FMT relieved symptoms compared with placebo (a

113 year-old male presented with upper abdominal bloating followed by modest hematemesis that led to the

114 ported diarrhea, constipation, flatulence or bloating, frequent stools, mucus in stools, or false urg

115 specific FGIDs of IBS, functional abdominal bloating, functional constipation and pelvic floor dyssy

116 Irritable bowel syndrome (IBS), functional bloating, functional constipation, and functional diarrh

117 Its symptoms include chronic abdominal pain, bloating gas, diarrhea and constipation.

118 age articles beginning with those related to bloating, gas, and IBS.

119 g (1.06 [1.50] vs 0.53 [0.90]; P = .73), and bloating/gas (3.28 [1.71] vs 2.23 [1.72]; P = .05) at th

120 onsistency, straining, abdominal discomfort, bloating, global assessments, and quality of life.

121 ease(3-5), can improve nutrition and prevent bloat in ruminant animals(6) and enhance soil nitrogen r

122 mportant agronomic trait, preventing pasture bloat in ruminant animals.

123 s in forage legumes for reduction of pasture bloat in ruminant animals.

124 Symptoms were respectively: bloating in 57%, diarrhea in 76% and abdominal pain in 4

125 inal bacterial overgrowth (SIBO) may explain bloating in IBS is supported by greater total hydrogen e

126 n is used most frequently, but postoperative bloating, inability to belch, and dysphagia occur.

127 l phase (P < 0.001) and those of swelling or bloating increased twofold to threefold during early men

128 The combination of bloating, increased abdominal size, and urinary symptoms

129 Among the most notorious of these are the bloated models caused by the large number of parameters,

130 5 gastrointestinal symptoms (abdominal pain, bloating, nausea, gas, and fullness) before breakfast an

131 paradigms without basal expression generate bloated networks with non-functional elements.

132 Neither bloating nor distention in IBS was related to body mass

133 Diarrhea, constipation, nausea, vomiting, or bloating occurred more frequently with efpeglenatide tha

134 expansion of the gastrosome and the dramatic bloating of the cell.

135 ed distension of the outer unit membrane and bloating of the internal mitochondrial compartment.

136 Bloating of the intestinal lumen also activates a broad

137 Here, we show that bloating of the intestinal lumen of Caenorhabditis elega

138 We propose that microbial colonization and bloating of the intestine may be perceived as a danger s

139 Instead, intestinal infection and bloating of the lumen, which depend on the virulence of

140 The relationship between the sensation of bloating, often ranked as the most bothersome symptom by

141 , abdominal pain, postprandial fullness, and bloating) on a 0-10 scale.

142 bility, sadness, anxiety, food cravings, and bloating) on dutasteride compared with placebo.

143 lobal symptoms, abdominal pain, or abdominal bloating or distension persisting after therapy, with a

144 For abdominal bloating or distension there was very low certainty in t

145 unctional diarrhea, 2.0%-3.9% for functional bloating or distention, 1.1%-1.9% for opioid-induced con

146 t symptom (constipation, diarrhoea, pain, or bloating) or combination of symptoms is the next step.

147 including nausea, vomiting, abdominal pain, bloating, or fullness; and safety according to total adv

148 absorption of partially digested food causes bloating, overfilled intestines, abdominal pain, excessi

149 ain effect of anxiety levels on fullness and bloating (P < .04), and of depression levels on abdomina

150 al pain (p < 0.01), loose stools (p < 0.01), bloating (p < 0.05), flatulence (p < 0.01), urgency (p <

151 somatization-by-time interaction effects for bloating (P = .005), and nausea (P = .02), and a nonsign

152 d the number of days with moderate to severe bloating (p = 0.03) and the proportion of patients with

153 (P-treatment x time interaction < 0.05), and bloating (P-treatment x time interaction < 0.001) compar

154 63 (abdominal pain, P = .231), 0.96 vs 3.29 (bloating, P = .204), and 0.02 vs 3.20 (tiredness, P = .1

155 Bloating, pain, and passage of wind also were reduced wh

156 ple, in females aged 50 to 59 with abdominal bloating, pre-blood test cancer risk of 1.6% increased t

157 ry care within 3 months of abdominal pain or bloating presentations.

158 defects in the DMP, resulting in intestinal bloating, rapid colonization of the gut by bacteria, and

159 vels of PAs reached values that would confer bloat reduction in forage species.

160 e 92% of these patients share the symptom of bloating regardless of their predominant complaint.

161 inability to belch, and inability to relieve bloating remained lower after 180-degree LAF.

162 0.67; 95% CI, 0.35-1.28; P-score = .86), and bloating (RR 0.53; 95% CI, 0.30-0.93; P-score = .97), ba

163 evention by dietary means or development of 'bloat-safe' forages.

164 consuming gluten (P = .049), as was the GSRS bloating score (P = .003).

165 n addition, rifaximin recipients had a lower bloating score after treatment.

166 d adults with IBS-D, mean abdominal pain and bloating scores of 3 or more, and loose stool, located a

167 ns with pain, burning sensation, nausea, and bloating scores.

168 controls; increases correlated with pain and bloating scores.

169 ic screen for mutations able to suppress the bloated sensory compartments of daf-6 mutants, we identi

170 d, with strong correlations existing between bloating/shrinkage during sintering, density and water a

171 at 5 years, except chest pain, diarrhea, and bloat symptoms which were more common after repair with

172 bowel habit, reported significantly greater bloating than controls (P < .0001).

173 ) causing symptoms ranging from postprandial bloating to recurrent vomiting.

174 m of the neurotransmitter reuptake symporter bloated tubules (blot), whose Drosophila ortholog has bo

175 Symptoms of bloating usually indicate the irritable bowel syndrome,

176 nting to primary care with abdominal pain or bloating warrant consideration for urgent cancer referra

177 erapy in patients with predominant abdominal bloating, we studied efficacy of this treatment in a ran

178 Mean scores for GSRS-IBS bloating were 9.3 +/- 3.5, 11.6 +/- 3.5, and 10.1 +/- 3.

179 pain and 1,148/52,321 (2.2%) with abdominal bloating were diagnosed with cancer within 12 months pos

180 Pain, nausea, and bloating were rated during baseline and distentions (0-5

181 ients who had adequate relief of IBS-related bloating, were assessed weekly.

182 es excessive gas production) and feelings of bloating (which are usually unrelated to excessive gas p

183 (P < 0.05) increase in feelings of abdominal bloating (which the participants perceived as excessive

184 Most patients had abdominal pain and bloating, which resolved with the diet.

185 a single mitochondrial genome that is merely bloated with AT-rich spacer DNA.

186 The liver in the fasted state is therefore bloated with LDs but, remarkably, still continues to sec